Replies to post #679488 on NorthWest Biotherapeutics Inc (NWBO)

[iclight]

The post to which you are referring has nothing to do with Direct. True, neither one work, but this is specifically regarding the tiny L trial with very few GBM patients, only 6% (one patient) reaching 60 months. If anything, this just highlights that the P3 uses the least effective treatment which is why they didn't compare it to an actual control arm.

If we are digging up old trials, might as well regurgitate the long term survival of the early ICT-107 trial :

With a long term follow up, we identified 3(19%) of 16 the GBM patients were disease free over 8 years (PFS 9.1+, 8.5+, 8+) and 6 (38%) patients (5 males, 1 female, KPS 90%, age range 34–62 years old at age of diagnosis) >6 years (range 6.1- 9 years).

That's 7 of 16 patients in the trial over 5 year survival. That's why we run P3 RCTs with a control arm folks.